Journal of Medical Genetics 2009;46:458-464
LETTERS TO JMG
Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinsons disease
1 INSERM, UMR_S679, Paris, France
2 Université Pierre et Marie Curie-Paris6, UMR_S679, Pitié-Salpêtrière, Paris, France
3 AP-HP, Groupe Pitié-Salpêtrière, Fédération des Maladies du Système Nerveux, Paris, France
4 Service de Neurologie, Centre Hospitalier Universitaire, Pointe-à-Pitre, Guadeloupe
5 Service de Neurologie, Hôpital Haut-Lévêque, Pessac, France
6 CHU Nantes, CIC0004, Service de Neurologie, Nantes, France
7 Unité 401, Pôle des Spécialités Neurologiques, Hôpital Neurologique Pierre Wertheimer, Bron, France
8 Département de Neurologie, CHU de Grenoble, Grenoble, France
9 Centre dInvestigation Clinique, Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, CHU Toulouse, Toulouse, France
10 EA2683, Service de Neurologie, Hôpital R. Salengro, CHRU de Lille, Lille, France
11 Pôle Tête-Cou-CETD, Service de Neurologie, Hôpitaux Universitaires, Strasbourg, France
12 INSERM, U763, Centre Hospitalier Universitaire, Pointe-à-Pitre, Guadeloupe
13 AP-HP, Groupe Pitié-Salpêtrière, Département de Génétique, Cytogénétique et Embryologie, Paris, France
Dr A Brice, INSERM UMR_S679, Hôpital de la Salpêtrière, 47, Boulevard de lHôpital, 75651 Paris cedex 13, France; alexis.brice{at}upmc.fr
Background: Mutations in the leucine-rich-repeat kinase 2 (LRRK2) gene have been identified in families with autosomal dominant Parkinsons disease (ADPD), the most common of which is the p.G2019S substitution that has been found at varying frequencies worldwide. Because of the size of the LRRK2 gene, few studies have analysed the entire gene in large series of ADPD families.
Methods: We performed extensive mutation analyses of all 51 coding exons of the LRRK2 gene in index cases from 226 Parkinsons disease families compatible with autosomal dominant inheritance, mostly from France (n = 182) and North Africa (n = 14).
Results: We found 79 sequence variants, 29 of which were novel. Eight potentially or proven pathogenic mutations were found in 22 probands (9.7%). There were four novel amino acid substitutions that are potentially pathogenic (p.S52F, p.N363S, p.I810V, p.R1325Q) and two novel variants, p.H1216R and p.T1410M, that are probably not causative. The common p.G2019S mutation was identified in 13 probands (5.8%) including six from North Africa (43%). The known heterozygous p.R1441H and p.I1371V mutations were found in two probands each, and the p.E334K variant was identified in one single patient. Most potentially or proven pathogenic mutations were located in the functional domains of the Lrrk2 protein.
Conclusion: This study leads us to conclude that LRRK2 mutations are a common cause of autosomal dominant Parkinsons disease in Europe and North Africa.
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
